[A25-48] Ciltacabtagene autoleucel (multiple myeloma) – Addendum to Project A24-116
Last updated 15.05.2025
Project no.:
A25-48
Commission:
Commission awarded on 08.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide
- Patients with 1 to 3 prior therapies for whom daratumumab in combination with pomalidomide and dexamethasone (DPd) or pomalidomide in combination with bortezomib and dexamethasone (PVd) is a suitable individualized treatment:
After addendum now: hint of considerable added benefit - Patients with 1 to 3 prior therapies for whom DPd or PVd is not a suitable individualized treatment, and patients with ≥ 4 prior therapies: added benefit not proven
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-48
| Project no. | Title | Status |
|---|---|---|
| A24-116 | Ciltacabtagene autoleucel (multiple myeloma, at least one prior therapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-05-15 A G-BA decision was published.